573764-31-5

Basic information

• Product Name: 4-CHLORO-3-IODOANILINE
• Synonyms: 4-CHLORO-3-IODOANILINE;4-Chloro-3-iodoaniline 97%;BenzenaMine, 4-chloro-3-iodo-;4-Chloro-3-iodo-phenylamine;4-Chloro-3-iodoaniline97%
• CAS NO: 573764-31-5
• Molecular Formula: C₆H₅ClIN
• Molecular Weight: 253.47
• Mol File: 573764-31-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 70 °C
• Boiling Point: 322.297 °C at 760 mmHg
• Flash Point: 148.72 °C
• Appearance: /
• Density: 2.016 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.00±0.10(Predicted)
• CAS DataBase Reference: 4-CHLORO-3-IODOANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-3-IODOANILINE(573764-31-5)
• EPA Substance Registry System: 4-CHLORO-3-IODOANILINE(573764-31-5)

Safety Data

• Hazardous Substances Data: 573764-31-5(Hazardous Substances Data)

Usage

General Description

4-CHLORO-3-IODOANILINE is a chemical compound with the molecular formula C6H5ClIN. It is a halogen-substituted aniline that is commonly used in the synthesis of various pharmaceuticals, agrochemicals, and dyes. 4-CHLORO-3-IODOANILINE is considered to be mildly toxic, and can cause irritation to the skin, eyes, and respiratory tract upon exposure. It is also considered to be a potential environmental hazard, as it is persistent in soil and water. Therefore, proper handling and disposal methods should be followed when working with 4-CHLORO-3-IODOANILINE to minimize its impact on human health and the environment.

Upstream product

• 62-53-3 aniline 
• 106-47-8 4-chloro-aniline 
• 100-00-5 4-chlorobenzonitrile 
• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 74534-15-9 1-chloro-2-iodo-4-nitrobenzene 
• 7439-89-6 iron 
• 32337-97-6 1-chloro-2-iodo-3-nitrobenzene 

Downstream Products

• 879088-69-4 N-(4-chloro-3-iodophenyl)-6-(trifluoromethyl)-2-methylpyridine-3-carboxamide 
• 1552310-42-5 ethyl 7-(3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)heptanoate 
• 1552310-58-3 ethyl 2-(3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)pyrimidine-5-carboxylate 
• 879088-41-2 4-chloro-3-(pyridin-2-yl)benzeneamine 
• 1552310-67-4 tert-butyl 4-((3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)methyl)piperidine-1-carboxylate 
• 1552310-69-6 ethyl 2-(4-((3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)methyl)piperidin-1-yl)pyrimidine-5-carboxylate 
• 1552310-98-1 ethyl 4-(2-(3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)phenyl sulfonamido)ethoxy)benzoate 
• 1552310-33-4 (E)-methyl-3-(6-(2-chloro-5-(2-chloro-4-(methylsulfonyl)benzamido)phenyl)pyridin-3-yl)acrylate 
• 1370525-64-6 2-chloro-N-[4-chloro-3-(5-hydroxy-2-pyridyl)phenyl]-4-methylsulfonylbenzamide 
• 1314306-02-9 2-chloro-N-(4-chloro-3-iodophenyl)-4-methylsulfonylbenzamide 
• 181633-37-4 4-chloro-3-(pyridin-3-yl)aniline 

Relevant articles and documents

AN IMPROVED ONE POT, ONE STEP PROCESS FOR THE HALOGENATION OF AROMATICS USING SOLID ACID CATALYSTS

The present invention disclosed an improved one pot, one step process for halogenation of compound of formula (II) to afford corresponding halogenated compound of formula (I) having improved yield and increased selectivity under very mild conditions.

Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings

PI3K/Akt/mTOR and hedgehog (Hh) signalings are two important pathways in breast cancer, which are usually connected with the drug resistance and cancer migration. Many studies indicated that PI3K/Akt/mTOR inhibitors and Hh inhibitors displayed synergistic effects, and the combination of the two signaling drugs could delay drug resistance and inhibit cancer migration in breast cancer. Therefore, the development of molecules simultaneously inhibiting these two pathways is urgent needed. Based on the structures of PI3K inhibitor buparlisib and Hh inhibitor vismodegib, a series of hybrid structures were designed and synthesized utilizing rational drug design and computer-based drug design. Several compounds displayed excellent antiproliferative activities against several breast cancer cell lines, including triple-negative breast cancer (TNBC) MDA-MB-231 cell. Further mechanistic studies demonstrated that the representative compound 9i could inhibit both PI3K/Akt/mTOR and hedgehog (Hh) signalings by inhibiting the phosphorylation of S6K and Akt as well as decreasing the SAG elevated expression of Gli1. Compound 9i could also induce apoptosis remarkably in T47D and MDA-MB-231 cells. In the transwell assay, 9i showed significant inhibition on the migration of MDA-MB-231.

HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The com-pounds can be used in methods of treating proliferative dis-eases and disorders such as cancer